ライフサイエンスコーパス: broadly neutralizing antibody

1 some that could escape from an RBS-targeted broadly neutralizing antibody.

2 ventative or therapeutic strategies based on broadly neutralizing antibodies.

3 ts and macaques, but so far failed to induce broadly neutralizing antibodies.

4 ts of recognition by some of the most potent broadly neutralizing antibodies.

5 al immunity, such as therapeutic vaccines or broadly neutralizing antibodies.

6 dition to the MPER on gp41 for generation of broadly neutralizing antibodies.

7 al for virus entry, is recognized by several broadly neutralizing antibodies.

8 cines against HIV most likely need to elicit broadly neutralizing antibodies.

9 cting virus, which in some cases mature into broadly neutralizing antibodies.

10 e relatively resistant to State 1-preferring broadly neutralizing antibodies.

11 orm the design of HIV-1 immunogens to elicit broadly neutralizing antibodies.

12 e, surface-presented Env, and are targets of broadly neutralizing antibodies.

13 necessary for the induction of Env-specific broadly neutralizing antibodies.

14 thus far to elicit production of potent and broadly neutralizing antibodies.

15 BG505, which is preferentially recognized by broadly neutralizing antibodies.

16 components of binding epitopes for numerous broadly neutralizing antibodies.

17 the germline B cell receptor forms of known broadly neutralizing antibodies.

18 sensitive for detection of many of the known broadly neutralizing antibodies.

19 bs); however, gp120 immunogens do not elicit broadly neutralizing antibodies.

20 transmission of HIV in humanized mice using broadly neutralizing antibodies.

21 minal fusion peptide that can be targeted by broadly neutralizing antibodies.

22 But humans can produce broadly neutralizing antibodies.

23 nsive effort to identify a vaccine to elicit broadly neutralizing antibodies.

24 ute to or influence the epitopes of numerous broadly neutralizing antibodies.

25 of a conserved epitope that is the target of broadly neutralizing antibodies.

26 that may lead to the eventual elicitation of broadly neutralizing antibodies.

27 e MPER region, demonstrated competition with broadly neutralizing antibodies 2F5 and 4E10, and exerte

28 quences that are binding sites for the HIV-1 broadly neutralizing antibodies 2F5, 4E10, and 10E8, mak

29 coprotein subunit gp41 is targeted by potent broadly neutralizing antibodies 2F5, 4E10, and 10E8.

30 Recently, an affinity column containing the broadly neutralizing antibody 2G12 has been used to capt

31 an(s), we selected variants that bind to HIV broadly neutralizing antibody 2G12 with picomolar to low

32 The broadly neutralizing antibody 447-52D targets the highly

33 e anti-HIV-1 envelope glycoprotein 41 (gp41) broadly neutralizing antibody 4E10 suggest that 4E10 als

34 accine development is to generate protective broadly neutralizing antibodies, a process dependent on

35 examine how a particularly potent family of broadly neutralizing antibodies (Abs) has evolved common

36 Development of high avidity, broadly neutralizing antibodies (Abs) is a priority afte

37 ghly immunogenic in cotton rats and elicited broadly neutralizing antibodies against a diverse panel

38 s potential vaccinology strategies to elicit broadly neutralizing antibodies against coronaviruses.

39 properties.IMPORTANCE One approach to elicit broadly neutralizing antibodies against HIV-1 is to stab

40 re contacts for recognition by V1V2-targeted broadly neutralizing antibodies against HIV-1.

41 at interest as immunogens which might elicit broadly neutralizing antibodies against HIV.

42 membranes, similar to the action of certain broadly neutralizing antibodies against influenza hemagg

43 Induction of broadly neutralizing antibodies against most HCV genotyp

44 We show that the binding of broadly neutralizing antibodies against quaternary-struc

45 ementarity-determining region loops of human broadly neutralizing antibodies against the hemagglutini

46 to how antibodies develop, in particular for broadly-neutralizing antibodies against HIV and influenz

47 iruses with neutralization titers against 16 broadly neutralizing antibodies and 30 sera from chronic

48 Ideally, the stimulation of both broadly neutralizing antibodies and cell-mediated immune

49 acterization and development of HIV-targeted broadly neutralizing antibodies and cytolytic T lymphocy

50 n could be used for increasing the levels of broadly neutralizing antibodies and for priming the huma

51 view the basic structural characteristics of broadly neutralizing antibodies and how they recognize t

52 ucts recapitulate the epitopes recognized by broadly neutralizing antibodies and induce broadly prote

53 HIV-1 envelope trimer (Env) is the target of broadly neutralizing antibodies and is being explored as

54 Several broadly neutralizing antibodies and retroviral inhibitor

55 nd colleagues describe the co-evolution of a broadly neutralizing antibody and the virus that trigger

56 izing antibodies, especially the epitopes of broadly neutralizing antibodies, and these mutations ten

57 IV-1 vaccine is of paramount importance, and broadly neutralizing antibodies are likely to be a key c

58 These so-called broadly neutralizing antibodies are readily detected in

59 mune responses, however, and the epitopes of broadly neutralizing antibodies are unknown.

60 might provide mechanistic insights into how broadly neutralizing antibodies arise.

61 we report that passive immunization with the broadly neutralizing antibody b12 protected humanized mi

62 Broadly neutralizing antibodies (bNAb) that target a con

63 ll-studied problems: finding the epitopes of broadly neutralizing antibodies (bNab), determining core

64 urse of infection from before they developed broadly neutralizing antibody (bNAb) activity until seve

65 that are recognized by trimer cross-reactive broadly neutralizing antibody (bnAb) and not by nonneutr

66 evolution and structural changes involved in broadly neutralizing antibody (bnAb) development holds g

67 Thus, most broadly neutralizing antibody (bNAb) epitopes were prese

68 is design of immunogens that can generate a broadly neutralizing antibody (bnAb) response against th

69 Elicitation of broadly neutralizing antibody (bNAb) responses is a majo

70 While many barriers to vaccine induction of broadly neutralizing antibody (bNAb) responses remain, e

71 During hepatitis C virus (HCV) infection, broadly neutralizing antibody (bNAb) responses targeting

72 Inducing cross-reactive broadly neutralizing antibody (bNAb) responses to HIV th

73 t is an ability to elicit strong and durable broadly neutralizing antibody (bNAb) responses.

74 VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active agai

75 A major obstacle to a broadly neutralizing antibody (bnAb)-based HIV vaccine i

76 The growing availability of HIV-1 broadly neutralizing antibodies (BNAbs) affords the oppo

77 ction of HIV-1 patients are able to generate broadly neutralizing antibodies (bNAbs) after 2 to 4 yea

78 idenced by the induction of higher titers of broadly neutralizing antibodies (bNAbs) against cell cul

79 The recent identification of three broadly neutralizing antibodies (bnAbs) against gp120-gp

80 d 13] were associated with the generation of broadly neutralizing antibodies (bnAbs) against HIV in a

81 Broadly neutralizing antibodies (bNAbs) against HIV-1 ar

82 e and proposes that engineered expression of broadly neutralizing antibodies (bNAbs) against HIV-1 co

83 e nnAbs are demonstrably less effective than broadly neutralizing antibodies (bNAbs) against HIV-1 in

84 A vaccine that elicits broadly neutralizing antibodies (bNAbs) against HIV-1 is

85 Broadly neutralizing antibodies (bnAbs) against HIV-1 pr

86 Efforts to elicit broadly neutralizing antibodies (bNAbs) against HIV-1 re

87 Development of broadly neutralizing antibodies (bnAbs) against HIV-1 us

88 The discovery of potent and broadly neutralizing antibodies (bNAbs) against human im

89 Broadly neutralizing antibodies (bNAbs) against human im

90 The discovery and characterization of broadly neutralizing antibodies (bnAbs) against influenz

91 cent discovery and characterization of human broadly neutralizing antibodies (bnAbs) against influenz

92 nd purified by affinity chromatography using broadly neutralizing antibodies (bNAbs) against quaterna

93 The identification of multiple broadly neutralizing antibodies (bNAbs) against the HIV-

94 Broadly neutralizing antibodies (bNAbs) against the HIV-

95 Broadly neutralizing antibodies (bnAbs) against the N332

96 Induction of broadly neutralizing antibodies (bnAbs) against this div

97 from 1 to 2 years postinfection (p.i.) with broadly neutralizing antibodies (bnAbs) against tier 2 H

98 Broadly neutralizing antibodies (bNAbs) against V1V2 loo

99 In this study, a panel of broadly neutralizing antibodies (bnAbs) and nnAbs, inclu

100 sted to quantify neutralization titers by 16 broadly neutralizing antibodies (bnAbs) and sera from 30

101 pe glycoprotein (Env) is the sole target for broadly neutralizing antibodies (bnAbs) and the focus fo

102 V3-glycan-targeting broadly neutralizing antibodies (bNAbs) are a focus of H

103 A subset of characterized HIV-1 broadly neutralizing antibodies (bnAbs) are polyreactive

104 ctive in humanized mice when combinations of broadly neutralizing antibodies (bNAbs) are used that ta

105 The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable tem

106 Broadly neutralizing antibodies (bNAbs) block infection

107 se trimers display the epitopes for multiple broadly neutralizing antibodies (bNAbs) but can also exp

108 ould expose as many epitopes as possible for broadly neutralizing antibodies (bNAbs) but few, if any,

109 Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelop

110 While the physical combination of two broadly neutralizing antibodies (bNAbs) can improve cove

111 Using humanized mice, we show that broadly neutralizing antibodies (bNAbs) can interfere wi

112 HIV-1-specific broadly neutralizing antibodies (bNAbs) can protect rhes

113 Induction of broadly neutralizing antibodies (bnAbs) capable of inhib

114 It is generally acknowledged that human broadly neutralizing antibodies (bNAbs) capable of neutr

115 The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of neutr

116 Such broadly neutralizing antibodies (bnAbs) could in the fut

117 HIV-1 broadly neutralizing antibodies (bnAbs) develop in a sub

118 ediates virus entry and is a major target of broadly neutralizing antibodies (bnAbs) developed during

119 ferred germline (iGL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs) did not display

120 Broadly neutralizing antibodies (bnAbs) directed to the

121 wever, mounting evidence suggests that these broadly neutralizing antibodies (bNAbs) do emerge natura

122 eficiency virus (HIV) envelope (Env) elicits broadly neutralizing antibodies (bnAbs) during natural i

123 Broadly neutralizing antibodies (bnAbs) elicited in HIV-

124 Most broadly neutralizing antibodies (BNAbs) elicited in resp

125 Understanding the mechanism(s) by which broadly neutralizing antibodies (bNAbs) emerge naturally

126 Recently discovered broadly neutralizing antibodies (bNAbs) exhibit remarkab

127 Here, we review how broadly neutralizing antibodies (bnAbs) exploit these ev

128 munized macaque suggests that elicitation of broadly neutralizing antibodies (bNAbs) for ebolaviruses

129 A new class of broadly neutralizing antibodies (bNAbs) from HIV donors

130 for antibody affinity maturation, with HIV-1 broadly neutralizing antibodies (bnAbs) generally requir

131 Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during

132 The discovery of broadly neutralizing antibodies (bNAbs) has provided an

133 Broadly neutralizing antibodies (bNAbs) have been evalua

134 Broadly neutralizing antibodies (bNAbs) have been isolat

135 Broadly neutralizing antibodies (bNAbs) have been isolat

136 HIV broadly neutralizing antibodies (bnAbs) have been shown

137 es of BG505 SOSIP.664 trimer in complex with broadly neutralizing antibodies (bNAbs) have revealed th

138 The structures of many broadly neutralizing antibodies (bNAbs) in complex with

139 ent is to define envelope (Env) evolution of broadly neutralizing antibodies (bnAbs) in infection and

140 enefit from understanding the development of broadly neutralizing antibodies (bnAbs) in rhesus macaqu

141 coprotein (Env) immunogen for elicitation of broadly neutralizing antibodies (bNAbs) is a challenging

142 Induction of broadly neutralizing antibodies (bNAbs) is a major goal

143 Induction of broadly neutralizing antibodies (bnAbs) is a major HIV v

144 Induction of broadly neutralizing antibodies (bnAbs) is a primary goa

145 Elicitation of broadly neutralizing antibodies (bnAbs) is a primary HIV

146 Induction of broadly neutralizing antibodies (bNAbs) is an important

147 trol of the HIV pandemic, and elicitation of broadly neutralizing antibodies (bnAbs) is likely to be

148 The elicitation of broadly neutralizing antibodies (bNAbs) is likely to be

149 l agents are the mainstay for treatment, but broadly neutralizing antibodies (bNAbs) may be a viable

150 an immunodeficiency virus (HIV-1) infection, broadly neutralizing antibodies (bnAbs) must be active a

151 120 envelope glycoprotein of HIV-1 and three broadly neutralizing antibodies (bNAbs) of the VRC01 cla

152 Broadly neutralizing antibodies (bNAbs) offer new avenue

153 The growing number of HIV-1 broadly neutralizing antibodies (BNAbs) offers the oppor

154 al., have repeatedly shown that HIV-specific broadly neutralizing antibodies (bnAbs) protect rhesus m

155 Studies of HIV-1 broadly neutralizing antibodies (bNAbs) provide valuable

156 Most broadly neutralizing antibodies (bnAbs) recognize these

157 of a preventative HIV vaccine able to elicit broadly neutralizing antibodies (bNAbs) remains a major

158 Broadly neutralizing antibodies (bNAbs) specific for con

159 Majority of the broadly neutralizing antibodies (bnAbs) targeting HIV-1

160 The identification of human broadly neutralizing antibodies (bnAbs) targeting the he

161 Broadly neutralizing antibodies (bnAbs) targeting the tr

162 the design of immunogens capable of inducing broadly neutralizing antibodies (bnAbs) that bind to the

163 of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs) that can prevent

164 ion, with only a subset of adults developing broadly neutralizing antibodies (bNAbs) that recognize v

165 Paradoxically, however, potent broadly neutralizing antibodies (bnAbs) that target this

166 Detailed studies of the broadly neutralizing antibodies (bNAbs) that underlie th

167 ss HIV-1 clades and the ability of anti-MPER broadly neutralizing antibodies (BNAbs) to block viral h

168 Induction of HIV-1 broadly neutralizing antibodies (bnAbs) to date has only

169 Broadly neutralizing antibodies (bnAbs) to HIV delineate

170 Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope

171 in (Delta123) increases the ability of human broadly neutralizing antibodies (bNAbs) to inhibit E2-CD

172 erapy against HIV-1 will most likely require broadly neutralizing antibodies (bnAbs) with maximum bre

173 A new generation of HIV broadly neutralizing antibodies (bnAbs) with remarkable

174 e patch on HIV Env is a preferred target for broadly neutralizing antibodies (bnAbs), but to date, no

175 Whereas broadly neutralizing antibodies (bNAbs), except for an M

176 -cycle viral infectivity and bind to several broadly neutralizing antibodies (bNAbs), including trime

177 Some HIV-1-infected human subjects develop broadly neutralizing antibodies (bnAbs), such as the pot

178 enza vaccines typically fail to elicit/boost broadly neutralizing antibodies (bnAbs), thereby limitin

179 es to the most recently described monoclonal broadly neutralizing antibodies (bNAbs), we confirmed a

180 Some HIV-infected individuals develop broadly neutralizing antibodies (bNAbs), whereas most de

181 me cases overlapped with those recognized by broadly neutralizing antibodies (bNAbs), whereas tier 1

182 Broadly neutralizing antibodies (bNAbs), whilst exhibiti

183 identification of a new generation of potent broadly neutralizing antibodies (bNAbs).

184 rstanding of the mechanisms of resistance to broadly neutralizing antibodies (bNAbs).

185 oprotein (Env) is the major target for HIV-1 broadly neutralizing antibodies (bNAbs).

186 ularly the elicitation of and recognition by broadly neutralizing antibodies (bnAbs).

187 e glycoprotein (Env) is targeted by multiple broadly neutralizing antibodies (bnAbs).

188 ystem but also acts as a target for anti-HIV broadly neutralizing antibodies (bnAbs).

189 inding site (CD81bs) that is a key target of broadly neutralizing antibodies (bNAbs).

190 s derived from multiple subtypes to generate broadly neutralizing antibodies (bNAbs).

191 inant epitopes could hinder the induction of broadly neutralizing antibodies (bNAbs).

192 virus (AAV) vectors can stably express HIV-1 broadly neutralizing antibodies (bNAbs).

193 cting as epitopes for a number of potent and broadly neutralizing antibodies (bnAbs).

194 ng conserved sites that are targets for some broadly neutralizing antibodies (bNAbs).

195 uccessful immunization approach for inducing broadly neutralizing antibodies (bnAbs).

196 the development of a vaccine that can elicit broadly neutralizing antibodies (bNAbs).

197 vaccine candidates aimed at the induction of broadly neutralizing antibodies (bNAbs).

198 ponent of the HIV envelope protein (Env) for broadly neutralizing antibodies (bnAbs).

199 Many HIV-1-infected patients evolve broadly neutralizing antibodies (bnAbs).

200 c diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs).

201 the target of vaccine development to elicit broadly neutralizing antibodies (bnAbs).

202 pe (Env) spike contains limited epitopes for broadly neutralizing antibodies (bNAbs); thus, most neut

203 rse HIV-1 primary virus isolates (designated broadly neutralizing antibodies [bNAbs]) remains a high

204 Broadly neutralizing antibodies bound tightly to all maj

205 ikes were recognized by all classes of known broadly neutralizing antibodies but not by non-neutraliz

206 Although passive transfer of anti-HIV-1 broadly neutralizing antibodies can protect mice or maca

207 istent with these observations, we find that broadly neutralizing antibodies can target CD4(+) T cell

208 The findings suggest that a single broadly neutralizing antibody can prevent acute HCV infe

209 ine field believe that the ability to elicit broadly neutralizing antibodies capable of blocking gene

210 the potency and magnitude of multiple HIV-1 broadly neutralizing antibody classes are decreased duri

211 ell control in primates, and host control of broadly neutralizing antibody elicitation have given ris

212 Several broadly neutralizing antibodies elicited from HIV patien

213 s founded by multiple distinct strains, with broadly neutralizing antibodies emerging earlier than in

214 Ideally, Env immunogens should present broadly neutralizing antibody epitopes but limit the pre

215 ndividual glycans are components of multiple broadly neutralizing antibody epitopes, while shielding

216 There are more ways to generate broadly neutralizing antibodies for influenza virus than

217 ralizing antibodies to HVR1 and by shielding broadly neutralizing antibodies from their epitopes.

218 mergence of pandemic strains, a new class of broadly neutralizing antibodies has been recently discov

219 V-1 Env in modulating epitope recognition by broadly neutralizing antibodies has not been well define

220 Influenza virus stem-reactive (SR) broadly neutralizing antibodies have been detected by sc

221 Broadly neutralizing antibodies have been isolated that

222 r, to date, HIV-1 Env immunogens that elicit broadly neutralizing antibodies have not been identified

223 Complexes of Env trimers with broadly neutralizing antibodies have surprisingly illust

224 The broadly neutralizing antibodies HIV 2F5 and 4E10, which

225 he critical CDR-H2 Phe54 (F-alleles) to make broadly neutralizing antibodies (HV1-69-sBnAb) to the in

226 scribe the X-ray structures of four of these broadly neutralizing antibodies in complex with the enve

227 Their results support the use of broadly neutralizing antibodies in HIV-reservoir-purging

228 hether infection with a novel strain induced broadly neutralizing antibodies in humans.

229 ces observed in the functional properties of broadly neutralizing antibodies in polyclonal contexts w

230 this probe proved that the patient produced broadly neutralizing antibodies in response to the vacci

231 ization resistant HIV-1 variants can lead to broadly neutralizing antibodies in some infected individ

232 Using the structure of a broadly neutralizing antibody in complex with a conserve

233 llenges (median = 3) for infection, a single broadly neutralizing antibody infusion prevented virus a

234 inability of Env to elicit the production of broadly neutralizing antibodies is due to the inability

235 Elicitation of broadly neutralizing antibodies is essential for the dev

236 Broadly neutralizing antibodies isolated from infected p

237 A few broadly neutralizing antibodies, isolated from HIV-1 inf

238 rigin, maturation pathway, and prevalence of broadly neutralizing antibody lineages (Antibodyomics1,

239 promise in understanding the development of broadly neutralizing antibody lineages (bNAbs).

240 Together, these results indicate that these broadly neutralizing antibodies may contribute to the de

241 Broadly neutralizing antibodies may therefore be easier

242 Broadly neutralizing antibodies of multigravidae are not

243 st few years have seen the isolation of many broadly neutralizing antibodies of remarkable potency th

244 ns potentially favors binding by established broadly neutralizing antibodies; omission of several spe

245 erest, including those that in humans elicit broadly neutralizing antibodies or bind particular Ig ge

246 t strain-specific antibodies can evolve into broadly neutralizing antibodies or in some cases act as

247 In this study, we show that the broadly neutralizing antibody PGT121, which neutralized

248 ted CD4 T cells by the HIV envelope-specific broadly neutralizing antibody PGT121.

249 train B41 SOSIP.664 gp140, does not bind the broadly neutralizing antibody PGT151 and so was used her

250 he cytoplasmic tail and is stabilized by the broadly neutralizing antibody PGT151, at a resolution of

251 model to study the efficacy and mechanism of broadly neutralizing antibody protection against HIV acq

252 , our method provides critical insights into broadly neutralizing antibody recognition of Env, which

253 We apply this approach to PGT151, a broadly neutralizing antibody recognizing a combination

254 e the development of vaccines able to induce broadly neutralizing antibodies remains the ultimate goa

255 Proposed strategies to elicit broadly neutralizing antibodies require a deeper underst

256 ically infected individuals and found that a broadly neutralizing antibody response is protective and

257 bjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orth

258 high-yield subunit HCV vaccine that elicited broadly neutralizing antibody responses in preclinical t

259 er T cell function has in the elicitation of broadly neutralizing antibody responses in the context o

260 cells from the subjects who later developed broadly neutralizing antibody responses than those who d

261 ive association of A*03 with HIV-1-specific, broadly neutralizing antibody responses.

262 viduals by passively administered 3BNC117, a broadly neutralizing antibody, suggested that the effect

263 tameric complex, rhesus macaques can develop broadly neutralizing antibodies targeting multiple immun

264 Broadly neutralizing antibodies targeting quaternary epi

265 Broadly neutralizing antibodies targeting the Env glycan

266 Broadly neutralizing antibodies targeting the HIV-1 glyc

267 rove more capable of eliciting RBS-directed, broadly neutralizing antibodies than those produced from

268 cule, which represents a strategy to produce broadly neutralizing antibodies that are effective again

269 Broadly neutralizing antibodies that recognize conserved

270 increase the association of Env with potent broadly neutralizing antibodies that recognize the CD4-b

271 Of note, generation and identification of broadly neutralizing antibodies that target group 2 HAs

272 rement for accommodating glycans among known broadly neutralizing antibodies that target the glycan-s

273 However, the recent discovery of broadly neutralizing antibodies that target the hemagglu

274 xternal region (MPER, an important target of broadly neutralizing antibodies), the transmembrane doma

275 small number of infected individuals elicit broadly neutralizing antibodies, the bulk of the humoral

276 ve been shown to interact with other potent, broadly neutralizing antibodies; therefore, this region

277 an be exploited for eliciting high-affinity, broadly neutralizing antibodies through immunization wit

278 re recognized by some of the most potent and broadly neutralizing antibodies to date.

279 s to HVR1 blocks the binding and activity of broadly neutralizing antibodies to HCV.

280 No immunogen to date has reliably elicited broadly neutralizing antibodies to HIV in humans or anim

281 dies in experimental animals have shown that broadly neutralizing antibodies to HIV-1 can prevent inf

282 B cells expressing potent and broadly neutralizing antibodies to HIV-1 have been found

283 nable the natural evolution and selection of broadly neutralizing antibodies to HIV-1, providing a po

284 ncovered a new generation of far more potent broadly neutralizing antibodies to HIV-1.

285 on with natural immunity, we used a panel of broadly neutralizing antibodies to identify the immunoge

286 gene usage and CDR3 length, associated with broadly neutralizing antibodies to rapidly evolving viru

287 All previously characterized broadly neutralizing antibodies to the HIV-1 envelope gl

288 strains, a vaccine most likely has to induce broadly neutralizing antibodies to the HIV-1 envelope gl

289 ibitory antibodies and by blocking access of broadly neutralizing antibodies to their epitopes.

290 ays will help identify ideal combinations of broadly neutralizing antibodies to use for passive preve

291 lization of an HIV-1 strain resistant to the broadly neutralizing antibodies VRC01 and 3BNC117.

292 ralization of HIV-1 strains resistant to the broadly neutralizing antibodies VRC01 and 3BNC117.

293 diversity for the lineage that produced the broadly neutralizing antibody VRC01 through longitudinal

294 , 50-, and 200-fold higher than those of the broadly neutralizing antibody VRC01, the U.S. FDA-approv

295 We found that broadly neutralizing antibodies were induced, but levels

296 Recently, elicitation of broadly neutralizing antibodies which target the conserv

297 ing fragment (Fab) of the PGT145 antibody, a broadly neutralizing antibody which recognizes the trime

298 s to conformation-specific, HA stem-directed broadly neutralizing antibodies with high affinity.

299 of trimer development programs is to induce broadly neutralizing antibodies with the potential to in

300 ted that combines the specificity of a HIV-1 broadly neutralizing antibody with that of an antibody t